Innovation is crucial to fulfil the potential of industrial biotechnology for sustainable production of fuels, chemicals, materials, food and feed. Similarly, scientific and technological advances in environmental biotechnology are needed to enable novel approaches to water purification, and ‘waste-to-product’ processes thus contributing to a circular economy. Increased fundamental knowledge encompassing enzymes, microorganisms and processes are essential for progress in this field. The Department of Biotechnology covers this research area and, based on new insights, selects, designs and tests new biobased catalysts, micro-organisms, and processes.
The department encompasses five research sections:
26 April 2022
ERC Advanced Grant for chemical dream reactions with enzymesOne of the big societal challenges today, is that the chemical industry still consumes a considerable amount of energy and resources. “This is a global issue for most, if not all, chemicals that factories produce nowadays”, says researcher Frank Hollmann. He has received a 2.5 M€ ERC Advanced Grant from the European Union to help tackle this problem over the next five years, by engineering enzymes as a catalyst for chemical reactions.
15 April 2022
National Growth Fund finances Cellular AgricultureThe National Growth Fund of the Dutch government grants conditional funding of 60 million euros to the Cellular Agriculture consortium, whose goal is to produce and promote protein-rich food from cultivated cells. The TU Delft is one of the founders of the consortium, with Marcel Ottens as initiator of the line of research. The TU Delft, together with the companies PlanetBio, DSM, Meatable, CE Delft and others, forms a hub in Delft for this new field of work.
24 February 2022
Mark van Loosdrecht wins Novozymes Prize for 25 years of revolutionary wastewater treatmentThe development of new technologies for biological wastewater treatment is turning our view of sludge upside down. Microbiologist Mark van Loosdrecht receives the 2022 Novozymes Prize for his pioneering work in copying and reusing nature’s mechanisms in wastewater treatment and resource recovery. Van Loosdrecht: “Treating wastewater will become good business in the future.”
03 March 2016
A sustainable, good, affordable Hib vaccine for every childWith her doctoral research, TU Delft doctoral candidate Ahd Hamidi has made a major contribution to developing an innovative, scalable, affordable version of the Haemophilus influenzae (Hib) vaccine developed by Intravacc. This low-cost vaccine has now been used to protect 200 million children worldwide against Hib diseases such as meningitis, pneumonia, sepsis and otitis media. Hamidi has defended her dissertation at TU Delft on Thursday 3 March. Gram stain of Haemophilus influenzae type b bacterium Since the 1990s, children in high-income countries have been vaccinated on a large scale with Hib vaccine, which protects against Hib diseases such as meningitis. Since 1993, the Hib vaccine has also been included in the Dutch National Vaccination Programme. ‘The introduction of Hib-vaccine in developing countries was slow, mainly because of its relatively high price. Further, the local vaccine manufacturers didn’t had access to the technology needed for the production of the vaccine’, says Hamidi. In Intravacc’s Hib project she worked on process development, making a major scientific and social contribution to the availability of approved registered low-cost Hib vaccine. Her dissertation also discusses ways of optimising the process and thus reducing the cost price still further, an attractive option for both current or future partners want. Technology transfer and price reduction Hamidi’s research focused on process development and technology transfer to vaccine manufacturers in developing countries, and using mathematical models to improve process knowledge and investigate whether further process optimisation (cost reduction) is possible. In 2013, one of Intravacc’s partners marketed the Hib vaccine, as part of a combined vaccine including four others, through UNICEF at a price that was three times lower than that of existing Hib vaccines, thus bringing it within reach of large numbers of children. If a further price reduction can be achieved, the countries concerned would be able to bear the cost of the vaccine themselves in future. The knowledge gained in the Hib project has meanwhile been transferred successfully to local manufacturers in Indonesia, China (via Korea) and India. UNICEF and GAVI (the Global Alliance for Vaccines and Immunisation) are both involved in distributing the vaccine. Mathematical models Hamidi collaborated closely with experienced process designers and vaccine experts at such institutions as Intravacc (formerly the Netherlands Vaccine Institute (NVI) and the National Institute for Public Health and the Environment (RIVM)) and with various vaccine manufacturers in Indonesia, China, Korea and India. She used the Delft process design method and the knowledge of experts at TU Delft to develop the mathematical models. This enabled predictable models of the Hib process developed and performing sensitivity analyses on the Hib process, thus showing the impact of particular choices on cost. ‘This approach can help both current and future Hib partners to make choices, for example between the use of existing production facilities and building new ones, or the optimum scale of production,’ explains Hamidi. Other vaccines This rational Delft method of process design, says Hamidi, can also be used very efficiently to develop other vaccines. While the process was being developed it was decided to protect it with a patent: partners have a license and their production method protected. More information After graduating in Chemical Engineering (MSc) and Bioprocess Design (PDEng) at TU Delft, Hamidi started working for the forerunners of Intravacc as a process technologist and subsequently project manager and technology transfer expert. In her dissertation she shares the lessons learned from the Hib project so that similar technology transfer projects can benefit from the experience. The project will help to reduce child mortality, one of the UN Millennium Development Goals. Hamidi published in the renowned journal Biotechnology Process in January 2016: ‘ Process development of a new Haemophilus influenzae type b conjugate vaccine and the use of mathematical modeling to identify process optimization possibilities ’ Contact For more information about the dissertation 'Towards a sustainable, quality and affordable Haemophilus influenzae type b vaccine for every child in the world' , please contact A. Hamidi MSc, A.Hamidi@tudelft.nl / Ahd.Hamidi@intravacc.nl tel. +31 30 2742066 or Claire Hallewas (TU Delft Press Officer), firstname.lastname@example.org , +31 6 4095 3085.
03 February 2016
Interview by BNR radio with Peter Mooij about the fattest algeaTo produce biodiesel using algae, you can revert the best in Darwin's theory. For scientists, however clever on genetic engineering, nature still outwits us from Delft research Peter Mooij, TU Delft on BNR radio (in Dutch): "You need to reward an algea for the trick he does"
15 January 2016